DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Antiangiogenic antibody Avastin
Ranibizumab
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (ARMD), a common form of age-related vision loss. Some investigators believe that bevacizumab at an average cost of $42 a dose (in the U.S. ) is as effective as ranibizumab at an average cost of $1,593 a dose...
Antiangiogenic antibody Avastin - List of case studies
- Treatments
-
reflux medication Anti-EGFR therapy Anti-HSV antibody Anti-HZV antibody Anti-MM therapy Anti-MM induction ... Anti-platelet therapy Antiaggregant therapy Antiangiogenic antibody Avastin Antiarrhythmic treatment Antibiotic ...
- Drugs
-
Anti-oxidant supplements Anti-platelet therapy Antiangiogenic antibody Avastin Antiarrhythmic treatment Antibiotic Antibiotic ...
- Advanced Metastatic Colon Cancer
-
been accomplished by the combination chemotherapy and the antiangiogenic antibody Avastin. In the meantime, the patient has been started on a ...